IRCT20220209053979N1 IRCT 2022-06-24 Pars Darou A bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer in 24 healthy volunteers under fasting condition A cross over bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer 24 healthy volunteers under fasting condition 2022-07-21 anticipated 24 Complete https://irct.ir/trial/64246 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Basic scienece, Randomization description: Each volunteer is assigned a code. In this way, half of the codes in the first phase of sampling receive the test drug and half of them receive reference drug, and in the second phase of the study, vice versa. The group that took the test drug in the first phase will take the reference drug in the second phase and the group that received the reference drug in the first phase will take the test drug, Blinding description: The drug (test or reference drug) is removed from the original packaging the day before the study and packaged in small disposable containers. Therefore, it is not in the original packaging, none of the volunteer nor the prescriber know which drug is being delivered. Bioequivalence Investigation of bioequivalence of Rivaroxaban tablets manufactured by Pars Daroo company in comparison to the xarelto made by Bayer company. Intervention group: Plasma concentration of test and reference drug, and area below concentration-time curve of test and reference drug. No - There is not a plan to make this available Justification or reason for not sharing IPD is Pars Daroo factory may not allow us to publish data.